SofosbuvirOther Names: SOF, Sovaldi Drug Class: Opportunistic Infections and Coinfections
What is sofosbuvir?
Sofosbuvir is an
HCV infection is an of HIV. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems. To learn more about opportunistic infections, read the What is an Opportunistic Infection? fact sheet.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the (CDC), the (NIH), and the HIV Medicine Association of the Diseases Society of America (IDSA-HIVMA), and the Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus, prepared by the American Association for the Study of Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) both include recommendations on the use of sofosbuvir to treat chronic HCV infection in people also infected with HIV.
In addition to recommendations for the medicine’s use in treating chronic HCV infection, the guidelines and the guidance include recommendations on the of sofosbuvir to treat acute HCV infection. Off-label use refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used off-label.
What should I tell my health care provider before taking sofosbuvir?
Before taking sofosbuvir, tell your health care provider:
- If you are allergic to sofosbuvir or any other medicines.
- About any medical conditions you have or have had, for example, or liver problems.
- If you take a medicine called tipranavir.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Sofosbuvir, in combination with ribavirin or with peginterferon alfa and ribavirin, may cause birth defects or death of an unborn child. Pregnant women and men whose partners are pregnant should not use these medicines. (Women should not become pregnant during treatment with sofosbuvir plus ribavirin or with sofosbuvir plus peginterferon alfa and ribavirin. Two forms of effective birth control should be used to avoid pregnancy. Women should also not become pregnant for 6 months after they stop taking these medicines or for 6 months after their male partners stop taking these medicines.) Talk to your health care provider about possible risks with taking sofosbuvir when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Sofosbuvir may affect the way other medicines or products work, and other medicines or products may affect how sofosbuvir works. Ask your health care provider if there are interactions between sofosbuvir and the other medicines you take.
How should I take sofosbuvir?
Take sofosbuvir according to your health care provider’s instructions. Your health care provider will tell you how much sofosbuvir to take and when to take it. Before you start sofosbuvir and each time you get a refill, read any printed information that comes with your medicine.
How should sofosbuvir be stored?
- Store sofosbuvir at room temperature, 68°F to 77°F (20°C to 25°C), and always below 86°F (30°C).
- Do not use sofosbuvir if the original seal over the container opening is broken or missing.
- Keep sofosbuvir in its original container.
- Throw away sofosbuvir that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep sofosbuvir and all medicines out of reach of children.
Where can I find more information about sofosbuvir?
More information about sofosbuvir is available:
- Recommendations on the HIV-related use of sofosbuvir, from the Guidelines for the Prevention and Treatment of Opportunistic infections in HIV-Infected Adults and Adolescents, prepared by CDC, NIH, and IDSA-HIVMA
- Recommendations on the HIV-related uses of sofosbuvir, from the Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus, prepared by AASLD and IDSA
- Sofosbuvir-related research studies, from the AIDSinfo database of study summaries
The above Patient Version drug summary is based on the following FDA label(s): Tablet (film coated).
Last Reviewed: January 11, 2019